Compare Cassava Sciences Inc (FLNA) vs NetApp Inc. (NTAP) Price & Performance

FLNA trades at $0.8136, down 0.26% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent positive news includes FDA lifting a clinical hold on its epilepsy drug, enabling Phase 2a studies.

The outlook remains high-risk due to persistent negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include clinical trial execution and funding needs, while the FDA decision provides a potential catalyst for long-term investors focused on biotech turnaround stories.

NetApp (NTAP) trades at $231.05, down 2.03% today but maintains strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), a 19.19% net income margin, and 114.82% ROE. Recent AI infrastructure announcements, including partnerships with Oracle and Supermicro, highlight strategic positioning in the growing data storage market. Analyst consensus shows mixed sentiment with 38% buy ratings but a $219.30 price target below current levels.

NetApp presents a compelling growth story driven by AI infrastructure demand and strong profitability metrics. However, elevated valuation ratios (P/E 32.63, P/S 6.26) and technical overbought conditions (RSI near 78) suggest near-term caution. The stock's upside potential depends on continued execution of AI strategy and Q3 2026 earnings delivery against $2.60 EPS expectations.